Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Influenza Vaccine vs Standard Dose Egg-Based Inactivated Influenza Vaccine
NCT05514002Phase 4Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of influenza vaccine, recombinant hemagglutinin in influenza, sponsored by Centers for Disease Control and Prevention. Started Sep 2022; status: completed.
02
Drugs
influenza vaccine, recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05514002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514002.